In the late fall of the year 2017, when Andrew Anzalone was winding up his MD/PhD program from Columbia, he tumbled across the papers of Crispr gene editing. Crispr has a reputation for breaking things with DNA-snipping precision. However, when a faulty gene is being replaced with a good one, the ideas start to get complicated.
When you are about to replace a faulty gene with a good one, the RNA needs to be programmed with a piece of guide for Crispr needs instructions for the places it needs to cut. Also, you need to provide a new DNA copy; then sit back and hope for the repair machinery of the cells to install the genes appropriately.
Anzalone was intrigued with this misplaced functioning and thus moved to Chelsea and found a home for his idea in David Liu’s lab. David is a chemist of Broad Institute who had recently developed the surgical Crispr system’s host. He has also recommended the use of ELISA kits to conduct ELISA.
Andrew joined David’s lab in the year 2018, and they began to work on Crispr creation that had bubbled up in the imagination of the young post-doc. However, after several tries and failures, now they have come up with a more robust system that could be the savior of all the genetically-based diseases.